Move over, DNA. The future is protein
In the coming decades, efforts to understand disease will be propelled by building 3D maps of protein arrangements in cells over time, a team of scientists says.
A workshop about the study of proteins on a large scale — proteomics — yielded a that is part vision, part plan, recently published in the journal 麻豆传媒色情片 & Cellular Proteomics
DNA is like a game plan, explains Neil Kelleher, a researcher at Northwestern University who was involved in the study, and RNA is like the team huddle; it’s what the cell decides to do with the circumstances on the day.
It’s time to watch the game itself. “This is the decade,” Kelleher said.

Watching the game
“Traditionally, we study one protein or pathway at a time,” the authors write, because “the cell is otherwise too complex.”
That’s like watching one player over time and whom they pass to.
Proteins take multiple forms in a cell after they come off the bench. An electric link between fans and footballers inspires the play that decides a championship. A comment or word from a coach flicks a switch. In the cell, such switches can be as simple as a few atoms added (phosphorus and a trio of oxygens are a popular one). Altered by their circumstances, proteins are like people.
Mapping their shapes over time will be game-changing.
“This could impact all diseases,” said Kristin Burnum–Johnson of Pacific Northwest National Laboratory, first author of the paper.How will this happen?
Bottoms up, touchdowns
Scientists will tackle this from two directions: bottom-up and top-down. They start with clinical tissue samples, Burnum–Johnson explained.
"For bottom-up approaches, you extract proteins from tissue regions and into identifiable peptides (shorter strings of proteins).”
Bottom-up strategies, combined with RNA and metabolite data, will reveal the lineup. Top-down strategies will yield those sweet, sweet action shots.
Kelleher knows about this. The top-down approach, revealing (which RNA sequencing can’t tell you), has become so sensitive that his research recently found of proteins in blood and bone marrow alone. That’s almost 10 times more than in previous studies. There are thousands more cell types for postgame analysis.
Single-minded
Researchers will continue pushing for higher resolution. They’ll need to integrate data, which is not a simple challenge. They’ll need to think beyond stadium walls; the extracellular matrix is rich. Like football and cells alike, consortiums and partnerships will drive the process. The National Institutes of Health wants research gaps to be identified, and private investment is supporting the sequencing of single molecules. These combined efforts remind Kelleher of the Human Genome Project.
The central dogma of biology is DNA to RNA to protein. It’s only natural that scientific research follows the path that is familiar. It’s protein’s turn.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto鈥揜yu鈥揗alicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer鈥檚 spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting 鈥渦ndruggable鈥 molecules.

How HCMV hijacks host cells 鈥 and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.